News Daily News Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks Michael O'Riordan August 01, 2025
News Daily News Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data L.A. McKeown July 24, 2025
News Daily News AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review Todd Neale July 24, 2025
News Daily News Prepregnancy CV Health Portends Midlife Risks: CARDIA Analysis L.A. McKeown June 27, 2025
News Daily News Majority of US Adults Have High Long-term Risk of CVD: NHANES Michael O'Riordan June 13, 2025
News Conference News HRS 2025 GLP-1 Drugs May Have Role in Secondary Prevention of AF Todd Neale April 28, 2025
News Daily News Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds Michael O'Riordan April 25, 2025
News Daily News Oral GLP-1 Drug Shines in Phase III ACHIEVE-1 Trial, Lilly Says Caitlin E. Cox April 17, 2025
News Daily News Weekend Warriors Also See Mortality Benefits With Exercise Michael O'Riordan April 10, 2025
News Daily News GLP-1 Drugs in Diabetes Don’t Raise Suicidality Risk, New Data Confirm Caitlin E. Cox February 26, 2025
News Daily News ‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials Michael O'Riordan February 20, 2025
News Daily News Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations L.A. McKeown January 31, 2025
News Daily News US Football Fans Are Flooded With Ads for Unhealthy Foods Michael O'Riordan January 30, 2025
News Daily News Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study Michael O'Riordan January 22, 2025
News Features Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s? Michael O'Riordan January 17, 2025
News Daily News Global Study Shows Sugary Drinks Boosting Diabetes and CVD at Alarming Rates L.A. McKeown January 10, 2025
News Daily News GLP-1 Receptor Agonists Come With Broad Array of Benefits, Risks Todd Neale January 21, 2024